CD8A and neoplasm: Consistent with its superior antitumor efficacy, treatment of A375-tumor-bearing mice with a-CTLA4-TGFβRII resulted in a greater elevation in tumor-reactive IFN-γ-expressing CD8+ cells compared with treatment with a-CTLA-4 (Fig. 4c).